Telehealth Options for Ketamine Tablet Prescriptions
The expansion of telehealth during and after the COVID-19 pandemic coincided with growing interest in ketamine tablet therapy, giving rise to a new category of healthcare services: telehealth-based ketamine prescribing platforms. These companies allow patients to consult with a ketamine prescriber online and receive compounded ketamine tablet shipped to their home, without requiring in-person clinic visits.
How Telehealth Ketamine Prescribing Works
The typical telehealth ketamine tablet pathway involves:
- Online intake: Patient completes a detailed questionnaire about psychiatric history, current medications, prior treatments, and symptoms
- Safety screening: Platform reviews for contraindications (suicidal ideation, psychosis history, cardiovascular contraindications)
- Telehealth evaluation: Video or audio consultation with a licensed prescriber (typically a psychiatrist or psychiatric NP) to review history, answer questions, and determine candidacy
- Prescription: If appropriate, prescriber sends a prescription to a contracted compounding pharmacy
- Pharmacy fulfillment: Compounding pharmacy prepares and ships the ketamine tablet (troches, tablets, or other form) directly to the patient
- Follow-up: Scheduled video check-ins for monitoring response, adjusting dose, and renewing prescriptions
The entire process — from first contact to receiving medication — typically takes 1–2 weeks.
Regulatory Context
DEA Emergency Flexibilities
Telehealth ketamine prescribing became possible on a broad scale because of DEA emergency flexibilities issued during the COVID-19 public health emergency (PHE) in 2020. These flexibilities allowed prescribers to prescribe Schedule III controlled substances (including ketamine) via telehealth without requiring an in-person examination first.
These flexibilities were extended multiple times beyond the initial PHE period. As of 2024, the DEA had proposed new permanent rules governing telehealth prescribing of controlled substances, including a requirement for at least one in-person visit for certain controlled substances. The regulatory status of telehealth ketamine prescribing remains in flux — patients should check current regulations and platform compliance status.
State Prescribing Laws
In addition to DEA rules, state prescribing laws govern telehealth controlled substance prescribing. Some states have additional requirements:
- Some states require prescribers to be licensed in the state where the patient resides
- Some states have specific telemedicine prescribing restrictions for controlled substances
- Compounding pharmacies shipping across state lines must comply with regulations of both their home state and the destination state
Reputable telehealth platforms navigate these regulations; ask any platform about their compliance before proceeding.
Major Telehealth Ketamine Platforms
Several platforms operate in this space as of 2024. The landscape evolves rapidly — this list reflects platforms that were established and operational at the time of writing:
Session-Based Platforms
Some of the largest telehealth ketamine platforms use a structured session-based model. These platforms offer ketamine therapy with licensed clinician oversight, guided sessions through a dedicated app, and integration support. They typically use sublingual tablets and provide audio/visual therapeutic guides for the session experience.
Approach: Structured session-based model with therapeutic preparation and integration support built into the program.
Medically Focused Platforms
Certain platforms focus on a streamlined, science-based approach to at-home ketamine therapy. They use compounded ketamine troches and provide licensed prescriber consultations plus ongoing monitoring.
Approach: More medically focused with regular clinical check-ins.
Daily Low-Dose Platforms
Some telehealth platforms use a low-dose daily ketamine model rather than session-based higher doses — described as a "microdose" approach. Patients receive small daily doses intended to provide antidepressant augmentation without noticeable acute effects.
Approach: Daily low-dose maintenance; designed to minimize psychoactive experience while targeting antidepressant effect.
Holistic Integration Platforms
Other platforms combine ketamine therapy with integration coaching and mental health support. Their approach emphasizes the integration of the ketamine experience through therapist and coach support.
Approach: Holistic; combines pharmacology with ongoing integration support.
What to Look for in a Telehealth Ketamine Platform
Quality varies significantly. When evaluating a platform, consider:
Clinical Rigor of Evaluation
Good sign: Comprehensive intake questionnaire covering psychiatric history, medical history, all current medications, substance use history, prior psychiatric hospitalizations, and family history.
Red flag: Minimal screening that focuses more on credit card information than clinical history.
Provider Credentials
Good sign: Board-certified psychiatrists or certified psychiatric NPs; provider profiles available on the website; prescribers licensed in your state.
Red flag: Inability to identify who will be prescribing for you or vague descriptions of "licensed providers."
Exclusion Criteria
Good sign: Clear published exclusion criteria (e.g., active psychosis, uncontrolled hypertension, active bipolar mania, history of ketamine abuse, certain medications). Platforms that exclude some patients are taking safety seriously.
Red flag: Extremely permissive inclusion; "everyone qualifies" messaging.
Monitoring Protocol
Good sign: Regular scheduled video check-ins; validated symptom assessments (PHQ-9, GAD-7) at defined intervals; crisis protocol described.
Red flag: Prescriptions renewed with minimal follow-up; no clear process for managing adverse events.
Pharmacy Quality
Good sign: Uses PCAB-accredited compounding pharmacies; transparent about pharmacy name; potency testing confirmed.
Red flag: Vague about which pharmacy prepares the medication.
Transparency About Risks and Limitations
Good sign: Platform proactively discusses risks, limitations, and situations where in-person care would be more appropriate.
Red flag: Marketing-heavy with minimal risk disclosure.
Cost Comparison
Telehealth ketamine platforms typically bundle consultation and medication costs:
| Platform Type | Typical Monthly Cost (Approximate) |
|---|---|
| Telehealth platform (bundled) | $150–$400/month |
| Independent psychiatrist + compounding pharmacy | $300–$600/month (depends on visit frequency) |
| Ketamine infusion clinic (IV, monthly maintenance) | $500–$1,000/month |
| Spravato (with Passport copay card) | $10–$50/month |
Telehealth platforms often offer the most affordable access point for uninsured patients.
Limitations of Telehealth-Only Ketamine Care
Telehealth ketamine prescribing offers significant benefits but has real limitations:
No physical examination: A thorough in-person physical exam can identify contraindications that may not be apparent from questionnaires (e.g., undetected cardiovascular disease, signs of substance use).
Limited crisis capability: If a patient experiences significant psychiatric deterioration, the telehealth platform's capacity to respond is limited compared to a local prescriber.
Monitoring quality varies: Virtual monitoring of medication response and side effects is inherently less direct than in-person evaluation.
At-home administration risks: Without clinical monitoring, patients who experience severe adverse reactions are on their own to manage the situation.
Complex cases may be poorly served: Patients with significant comorbidities, complex psychiatric histories, or high suicide risk need in-person care, not telehealth ketamine.
When Telehealth Is and Is Not Appropriate
Telehealth ketamine is generally appropriate for:
- Patients with moderate depression or anxiety who have tried multiple treatments
- Patients who have previously been evaluated in person by a psychiatrist familiar with their history
- Patients who are geographically distant from in-person ketamine providers
- Patients who need maintenance therapy after stabilization with IV or in-clinic ketamine
In-person care is preferred for:
- Patients with active suicidal ideation
- Patients with significant psychiatric complexity (psychosis, bipolar I, severe PTSD)
- Patients with uncontrolled cardiovascular conditions
- Patients who are new to psychiatric treatment and have not had a thorough in-person evaluation
- Patients who had adverse experiences with prior ketamine treatment
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
- SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service
Share